Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZANGEA: Zanidatamab + Pembrolizumab + Chemotherapy in HER2+/PD-L1+ Metastatic GEA
NCT07176312Phase 2Recruiting
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Jan 2026
- Primary completion
- Mar 2029
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of zanidatamab in gastroesophageal adenocarcinoma, sponsored by Institut für Klinische Krebsforschung. Started Jan 2026; status: recruiting.
02
Drugs
zanidatamab
03
Conditions
gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NCT07176312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07176312.